Abstract

Breast cancer comprises a highly heterogeneous group of diseases. Many breast cancers, particularly the more lethal ones, may not satisfy the assumptions about biology and natural history of breast cancer necessary for screening mammography to be effective. To compare tumor characteristics of breast cancers diagnosed within 2 years of a normal screening mammogram (interval breast cancer [IBC]) with those of screen-detected breast cancers (SBC) and to compare breast cancer-specific mortality of IBC with SBC. In this registry-based cohort study, we collected data about relevant tumor- and patient-related variables on women diagnosed with breast cancer between January 2004 and June 2010 who participated in the population-based screening program in Manitoba, Canada, and those diagnosed with breast cancer outside the screening program in the province. We performed multinomial logistic regression analysis to assess tumor and patient characteristics associated with a diagnosis of IBC compared with SBC. Competing risk analysis was performed to examine risk of death by cancer detection method. Breast cancer diagnosis. Differences in tumor characteristics and breast cancer-specific mortality. A total of 69 025 women aged 50 to 64 years had 212 screening mammograms during the study period. There were 1687 breast cancer diagnoses (705 SBC, 206 IBC, 275 were noncompliant, and 501 were detected outside the screening program), and 225 deaths (170 breast cancer-specific deaths). Interval cancers were more likely than SBC to be of high grade and estrogen receptor negative (odds ratio [OR], 6.33; 95% CI, 3.73-10.75; P < .001; and OR, 2.88; 95% CI, 2.01-4.13; P < .001, respectively). After a median follow-up of 7 years, breast cancer-specific mortality was significantly higher for IBC compared with SBC cancers (hazard ratio [HR] 3.55; 95% CI, 2.01-6.28; P < .001), for a sojorn time of 2 years. Non-breast cancer mortality was similar between IBC and SBC (HR, 1.33; 95% CI, 0.43-4.15). In this cohort study, interval cancers were highly prevalent in women participating in population screening, represented a worse biology, and had a hazard for breast cancer death more than 3-fold that for SBC. Strategies beyond current mammographic screening practices are needed to reduce incidence, improve detection, and reduce deaths from these potentially lethal breast cancers.

Highlights

  • Screening mammography, performed every 2 to 3 years, has demonstrated a decrease in breast cancer–specific mortality by 10% to 25% in relative terms, but not overall mortality, compared with no screening.[1]

  • After a median follow-up of 7 years, breast cancer–specific mortality was significantly higher for Interval breast cancer (IBC) compared with screen-detected breast cancer (SBC) cancers, for a sojorn time of 2 years

  • Non–breast cancer mortality was similar between IBC and SBC (HR, 1.33; 95% CI, 0.43-4.15)

Read more

Summary

Introduction

Screening mammography, performed every 2 to 3 years, has demonstrated a decrease in breast cancer–specific mortality by 10% to 25% in relative terms, but not overall mortality, compared with no screening.[1]. Interval breast cancer (IBC) is the cancer detected after a normal screening mammogram but before the scheduled mammogram. IBC by definition defies assumptions necessary for screening mammography to be maximally effective. Few studies have suggested previously that IBCs represent higher grade tumors compared with screen-detected breast cancer (SBC), but the evidence on outcome of IBC compared with SBC is variable.[3,4,5] When the relationship between method of breast cancer detection and outcome is provided, the effect size is rather small.[6] In this study, we used a population-based cancer registry to compare the biology and outcomes of SBC with those of IBC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call